Company Overview and News
Real-estate marketplace Zillow Group Inc. Z, +1.05% said Monday it is expanding a marketing agreement with Realty Executives International to include listings from Canada on its mobile app and website. The company said it has more than 100 million visits from non-U.S. home seekers a year, a large number of whom are from Canada. Listings from several Canadian brokerages will soon be live on Zillow with a description and photos of each property with listing agent.
Gap Inc. GPS, -1.02% said Thursday that it has added three board members, effective November 1: Amy Bohutinsky, chief operating officer of Zillow Group Inc.; John Fisher, co-founder of Sansome Partners, an investment management firm; and Lexi Reese, chief operating officer of Gusto, a cloud-based human resources platform. Gap's apparel and accessories chains includes its namesake brand, Banana Republic and Old Navy.
ZG Z GPS
Shares of Zillow Group (ZG - Free Report) have gained 7.7% in the past one year, against the industry’s decline of 2.8%. The company’s price performance was driven by an impressive earnings surprise history. It surpassed earnings estimates in each of the trailing four quarters, recording an average beat of 18.2%.
GFN GFNCP ZG Z NTAP GFDV CRM GFNSL PAYC
2018-08-15 investorplace - 1
Redfin (NASDAQ:RDFN) plunged in trading following earnings. The Seattle-based real estate brokerage company lost over 22.4% of its value despite beating earnings and revenue expectations. Fears of a real estate slowdown in key metro areas weighed on RDFN stock.
RDFN ZG AMZN Z
TiVo Corporation (TIVO - Free Report) reported dismal results for second-quarter 2018 as its top and bottom line declined on a year-over-year basis. The company reported loss of 17 cents per share, wider than the year-ago quarter’s loss of 4 cents. The company’s non-GAAP earnings per share came in at 26 cents compared with 51 cents in the year-ago period. The Zacks Consensus Estimates for earnings was pegged at 27 cents.
ZG Z QLYS UCTI TIVO UCTT
CyberArk Software Ltd. (CYBR - Free Report) reported second-quarter 2018 non-GAAP earnings of 36 cents, which rose 71.4% from the year-ago quarter and surpassed the Zacks Consensus Estimate of 24 cents as well. CyberArk’s revenues were up 35.2% year over year to $77.7 million and came ahead of the Zacks Consensus Estimate of $73 million. The top line mainly benefited from better sales execution, customer acquisitions and add-on business from existing clients.
CYBR ZG OAS VRNT Z
3D Systems Corporation (DDD - Free Report) reported non-GAAP earnings of 6 cents per share for second-quarter 2018 compared with 8 cents in the year-ago quarter. The Zacks Consensus Estimate was pegged at breakeven. This 3D printer maker reported revenues of $176.6 million in the quarter, reflecting a year-over-year increase of 10.7%. Steady demand for the company’s healthcare, materials, software and on-demand manufacturing, along with increased printer unit sales proved conducive for the top line.
ZG OAS VRNT Z
Match Group (MTCH - Free Report) delivered second-quarter fiscal 2018 adjusted earnings of 41 cents per share, which surpassed the Zacks Consensus Estimate of 36 cents per share. Moreover, the figure increased from the year-ago earnings of 16 cents per share.
MTCH ELY ZG Z ICFI FTNT PAYC
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to ZG / Zillow Group, Inc. on message board site Silicon Investor.
as of ET